Mavacamten (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Mavacamten" in French language version.

refsWebsite

Global rank French rank

4sciencedirect.com

149^th place

80^th place

2ahajournals.org

3,608^th place

659^th place

485^th place

416^th place

731^st place

771^st place

9,562^nd place

535^th place

ahajournals.org

Desai MY, Owens A, Geske JB et al. Dose-blinded myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy: outcomes through 32 weeks, Circulation, 2023;147:850–863
Saberi S, Cardim N, Yamani MH et al. Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM CMR substudy analysis, Circulation, 2021;143:606–608

has-sante.fr

Mavacantem, avis de la commission de transparence, 28 septembre 2023

oup.com

academic.oup.com

Braunwald E, Saberi S, Abraham TP, Elliott PM, Olivotto I, Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy, European Heart Journal, 2023;Volume 44:4622–4633

sagepub.com

journals.sagepub.com

Dalo JD, Weisman ND, White M, Mavacamten, a first-in-class cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy, Annals of pharmacotherapy, 2023:57:489–502

sciencedirect.com

Olivotto I, Oreziak A, Barriales-Villa R et al. EXPLORER-HCM Study Investigators. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 2020;396:759–769
Desai MY, Owens A, Geske JB et al. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy, J Am Coll Cardiol, 2022;80:95–108
Spertus JA, Fine JT, Elliott P et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 2021;397:2467–75
Saberi S, Kramer CM, Oreziak A et al. [https://www.sciencedirect.com/science/article/pii/S0735109723007702 96 week cardiac magnetic resonance (CMR) results of treatment with mavacamten from the EXPLORER cohort of the Mava Long term Extension (LTE) study in patients with obstructive hypertrophic cardiomyopathy HCM), J Am Coll Cardiol, 2023;81:326